p38 Mitogen-Activated Protein Kinase (MAPK) in Rheumatoid Arthritis

J.      Westra; P.      C. Limburg

doi:10.2174/138955706777934982

Abstract

The importance of p38 MAPK inhibitors as new drug for rheumatoid arthritis is reflected by the large number of compounds that has been developed over the last years. In this review new insights such as non-stressful activation of p38 MAPK, and the role of p38 MAPK in regulation of NF-κB recruitment are also discussed.

Keywords: Rheumatoid arthritis, drug, p38 MAPK

« Previous Next »